Also interesting is that Lauren Chung from the Yozma Group Korea joined Aditxt as an Independent Board Member on June 18th.
Skip to content

Investor Relations
Media
PRESS RELEASESView All
June 18, 2021 8:00 AM
Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
As an independent director, Dr. Chung brings deep expertise in healthcare investment and corporate development
Aditx Therapeutics, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director.
“As a new independent director of Aditxt’s board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals,” said Amro Albanna, co-founder and CEO of Aditxt. “We look forward to working with Dr. Chung as we establish our portfolio of first-in-human clinical studies, launch new high-growth verticals for our AditxtScore TM immune intelligence platform, and explore partnership strategies across the globe.”
Dr. Chung has over 20 years of healthcare investment management, investment banking, and advisory experience, and is currently a venture partner at Yozma Group Korea. She is the founder and CEO of MINLEIGH LLC, which is focused on identifying, evaluating, and partnering with companies for investments and strategic, operational, and commercial opportunities.
Prior to her current roles, Dr. Chung was a managing director in Healthcare Research at WestPark Capital. Previously, she was a co-founder of Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners. Prior to that, Dr. Chung managed healthcare investment portfolios at institutional investment firms. Earlier in her career, Dr. Chung was a research scientist doing cutting-edge work in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital.
Dr. Chung has published in many leading peer-reviewed scientific journals, and as a current and former director of public and private companies, she brings a valuable perspective for the company’s strategy and operations, as well as extensive scientific insights.
About Aditxt:
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt’s immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com
Forward-Looking Statements:
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210618005027/en/
Media and Investor Relations Contact:
Sunny Uberoi
Chief Communications Officer
Aditxt
ir@aditxt.com
News Provided by Business Wire via QuoteMedia
Thu Aug 26th, 2021
Business Wire9:15 AM
Aditxt Announces Pricing of $11.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Wed Aug 25th, 2021
Business Wire9:16 AM
Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19
Thu Aug 12th, 2021
SEC Filings5:21 PM
General form for quarterly reports under Section 13 or 15(d) - Form 10-Q
Wed Aug 11th, 2021
Business Wire8:00 AM
Aditxt, Inc. and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic
Wed Aug 4th, 2021
Business Wire8:00 AM
Aditxt Provides Update on AditxtReprogramming's(TM) Apoptotic DNA Immunotherapy Therapeutic Platform
Tue Aug 3rd, 2021
SEC Filings3:00 AM
Current report pursuant to Section 13 or 15(d) - Form 8-K
Mon Jul 12th, 2021
Business Wire8:00 AM
Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19
Thu Jul 8th, 2021
SEC Filings5:08 PM
Current report pursuant to Section 13 or 15(d) - Form 8-K
Wed Jul 7th, 2021
Business Wire8:00 AM
Aditxt Opens its First High-Capacity Immune Monitoring Center in Richmond, VA
Tue Jul 6th, 2021
SEC Filings5:50 PM
[Amend] Registration statement under Securities Act of 1933 - Form S-3/A
Fri Jul 2nd, 2021
SEC Filings5:16 PM
Registration statement under Securities Act of 1933 - Form S-3
SEC Filings5:05 PM
[Amend] Annual report [Section 13 and 15(d), not S-K Item 405] - Form 10-K/A
Wed Jun 23rd, 2021
SEC Filings6:11 PM
Initial statement of beneficial ownership of securities - Form 3
Mon Jun 21st, 2021
SEC Filings6:00 PM
Current report pursuant to Section 13 or 15(d) - Form 8-K
Fri Jun 18th, 2021
Business Wire8:00 AM
Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
Tue Jun 15th, 2021
PR Newswire8:00 AM
Aditxt Set to Join Russell Microcap® Index
Tue Jun 8th, 2021
SEC Filings5:06 PM
Statement of changes in beneficial ownership of securities - Form 4
SEC Filings5:05 PM
Statement of changes in beneficial ownership of securities - Form 4
SEC Filings5:05 PM
Statement of changes in beneficial ownership of securities - Form 4
Fri Jun 4th, 2021
SEC Filings6:01 PM
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans - Form S-8
More News
JUMP TO
SEC FILINGS
CORPORATE GOVERNANCE

May 18, 2021
Shareholder Letter from Amro Albanna
View page
STOCK QUOTEView All
Aditxt Inc.(ADTX)
$1.97-0.16 | -7.51%r
Bid: 1.96 x 5200Ask: 1.98 x 2500
August 27, 2021 4:00 PMEDTVolume: 5,583,598
After Hours: $1.98 0.01 | 0.51%August 27, 2021 5:17 PMEDTVolume: 31,630
USDNASDAQ CAPITAL MARKETDELAYED PRICEMARKET CLOSED
CHARTINGView Full Chart
1D
5D
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
Volume:
Frequency
AILY
Combination chart with 2 data series.
QuoteMedia Interactive chart.
The chart has 1 X axis displaying Time. Range: 2021-01-02 07:35:00 to 2021-08-30 01:23:00.
The chart has 2 Y axes displaying Price and Volume.
PriceVolume<
Skip to content

Investor Relations
Media
PRESS RELEASESView All
June 18, 2021 8:00 AM
Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
As an independent director, Dr. Chung brings deep expertise in healthcare investment and corporate development
Aditx Therapeutics, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director.
“As a new independent director of Aditxt’s board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals,” said Amro Albanna, co-founder and CEO of Aditxt. “We look forward to working with Dr. Chung as we establish our portfolio of first-in-human clinical studies, launch new high-growth verticals for our AditxtScore TM immune intelligence platform, and explore partnership strategies across the globe.”
Dr. Chung has over 20 years of healthcare investment management, investment banking, and advisory experience, and is currently a venture partner at Yozma Group Korea. She is the founder and CEO of MINLEIGH LLC, which is focused on identifying, evaluating, and partnering with companies for investments and strategic, operational, and commercial opportunities.
Prior to her current roles, Dr. Chung was a managing director in Healthcare Research at WestPark Capital. Previously, she was a co-founder of Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners. Prior to that, Dr. Chung managed healthcare investment portfolios at institutional investment firms. Earlier in her career, Dr. Chung was a research scientist doing cutting-edge work in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital.
Dr. Chung has published in many leading peer-reviewed scientific journals, and as a current and former director of public and private companies, she brings a valuable perspective for the company’s strategy and operations, as well as extensive scientific insights.
About Aditxt:
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt’s immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com
Forward-Looking Statements:
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210618005027/en/
Media and Investor Relations Contact:
Sunny Uberoi
Chief Communications Officer
Aditxt
ir@aditxt.com
News Provided by Business Wire via QuoteMedia
Thu Aug 26th, 2021
Business Wire9:15 AM
Aditxt Announces Pricing of $11.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Wed Aug 25th, 2021
Business Wire9:16 AM
Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19
Thu Aug 12th, 2021
SEC Filings5:21 PM
General form for quarterly reports under Section 13 or 15(d) - Form 10-Q
Wed Aug 11th, 2021
Business Wire8:00 AM
Aditxt, Inc. and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic
Wed Aug 4th, 2021
Business Wire8:00 AM
Aditxt Provides Update on AditxtReprogramming's(TM) Apoptotic DNA Immunotherapy Therapeutic Platform
Tue Aug 3rd, 2021
SEC Filings3:00 AM
Current report pursuant to Section 13 or 15(d) - Form 8-K
Mon Jul 12th, 2021
Business Wire8:00 AM
Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19
Thu Jul 8th, 2021
SEC Filings5:08 PM
Current report pursuant to Section 13 or 15(d) - Form 8-K
Wed Jul 7th, 2021
Business Wire8:00 AM
Aditxt Opens its First High-Capacity Immune Monitoring Center in Richmond, VA
Tue Jul 6th, 2021
SEC Filings5:50 PM
[Amend] Registration statement under Securities Act of 1933 - Form S-3/A
Fri Jul 2nd, 2021
SEC Filings5:16 PM
Registration statement under Securities Act of 1933 - Form S-3
SEC Filings5:05 PM
[Amend] Annual report [Section 13 and 15(d), not S-K Item 405] - Form 10-K/A
Wed Jun 23rd, 2021
SEC Filings6:11 PM
Initial statement of beneficial ownership of securities - Form 3
Mon Jun 21st, 2021
SEC Filings6:00 PM
Current report pursuant to Section 13 or 15(d) - Form 8-K
Fri Jun 18th, 2021
Business Wire8:00 AM
Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
Tue Jun 15th, 2021
PR Newswire8:00 AM
Aditxt Set to Join Russell Microcap® Index
Tue Jun 8th, 2021
SEC Filings5:06 PM
Statement of changes in beneficial ownership of securities - Form 4
SEC Filings5:05 PM
Statement of changes in beneficial ownership of securities - Form 4
SEC Filings5:05 PM
Statement of changes in beneficial ownership of securities - Form 4
Fri Jun 4th, 2021
SEC Filings6:01 PM
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans - Form S-8
More News
JUMP TO
SEC FILINGS
CORPORATE GOVERNANCE

May 18, 2021
Shareholder Letter from Amro Albanna
View page
STOCK QUOTEView All
Aditxt Inc.(ADTX)
$1.97-0.16 | -7.51%r
Bid: 1.96 x 5200Ask: 1.98 x 2500
August 27, 2021 4:00 PMEDTVolume: 5,583,598
After Hours: $1.98 0.01 | 0.51%August 27, 2021 5:17 PMEDTVolume: 31,630
USDNASDAQ CAPITAL MARKETDELAYED PRICEMARKET CLOSED
CHARTINGView Full Chart
1D
5D
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
Volume:
Frequency
AILY Combination chart with 2 data series.
QuoteMedia Interactive chart.
The chart has 1 X axis displaying Time. Range: 2021-01-02 07:35:00 to 2021-08-30 01:23:00.
The chart has 2 Y axes displaying Price and Volume.
PriceVolume<
1
